Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Key Inclusion Criteria:~* Liver biopsy consistent with NASH and F3 or F4 in the opinion of the central reader~* In participants who have never had a liver biopsy, liver stiffness by FibroScan® ≥ 14.0 kPa and Enhanced Liver Fibrosis (ELF™) Test score ≥ 9.8 at Screening~* Screening laboratory parameters, as determined by the central laboratory:~  * Estimated glomerular filtration rate (eGFR) ≥ 60 mL/min, as calculated by the Cockcroft-Gault equation~ * Hemoglobin A1c (HbA1c) ≤ 9.5%~ * Alanine aminotransferase (ALT) \< 5 x Upper Limits of Normal (ULN)~ * Platelet count ≥ 125,000/μL~Key Exclusion Criteria:~* Prior history of decompensated liver disease including ascites, hepatic encephalopathy, or variceal bleeding~* Child-Pugh (CP) score \> 6 at Screening, unless due to an alternative etiology such as Gilbert's syndrome or therapeutic anticoagulation~* Model for End-Stage Liver Disease (MELD) score \> 12 at Screening, unless due to an alternate etiology such as therapeutic anticoagulation~* Other causes of liver disease based on medical history and/or centralized review of liver histology, including but not limited to: alcoholic liver disease, hepatitis B, hepatitis C, autoimmune disorders (eg, primary biliary cholangitis, primary sclerosing cholangitis, autoimmune hepatitis), drug-induced hepatotoxicity, Wilson disease, clinically significant iron overload, or alpha-1-antitrypsin deficiency requiring treatment~* History of liver transplantation~* Current or prior history of hepatocellular carcinoma~Note: Other protocol defined Inclusion/ Exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Selonsertib (SEL) (Type: EXPERIMENTAL): Participants will receive SEL + placebo to match firsocostat 20 mg tablet + placebo to match cilofexor 30 mg tablet orally once daily for 48 weeks.
- Firsocostat (FIR) (Type: EXPERIMENTAL): Participants will receive placebo to match SEL 18 mg tablet + FIR + placebo to match CILO 30 mg tablet orally once daily for 48 weeks.
- Cilofexor (CILO) (Type: EXPERIMENTAL): Participants will receive placebo to match SEL 18 mg tablet + placebo to match FIR 20 mg tablet + CILO orally once daily for 48 weeks.
- Selonsertib (SEL) + Firsocostat (FIR) (Type: EXPERIMENTAL): Participants will receive SEL + FIR + placebo to match CILO 30 mg tablet orally once daily for 48 weeks.
- Selonsertib (SEL) + Cilofexor (CILO) (Type: EXPERIMENTAL): Participants will receive SEL + placebo to match FIR 20 mg tablet + CILO orally once daily for 48 weeks.
- Firsocostat (FIR) + Cilofexor (CILO) (Type: EXPERIMENTAL): Participants will receive placebo to match SEL 18 mg tablet + FIR + CILO orally once daily for 48 weeks.
- Placebo (Type: EXPERIMENTAL): Participants will receive placebo to match SEL 18 mg + placebo to match FIR 20 mg tablet + placebo to match CILO 30 mg tablet orally once daily for 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete